Seeking a Diagnosis with a Rising PSA - Jelle Barentsz
(Length of discussion - 9 minutes)
Dr. Jelle Barentsz provides his perspective on treating a patient with a rising PSA and is seeking diagnosis options. During this discussion held at the Radiological Society of North America (RSNA) 2017 conference, he shares that he would not recommend a 12-core systematic biopsy because it is not targeted. 40% of patients with a trans-rectal ultrasound guided (TRUS) biopsies will reveal insignificant cancer, which will result in over-diagnosis. Dr. Barentsz recommends multiparametric MRI, which is quick, easy, and can significantly reduce over-diagnoses from 40% to 80%. He also discusses the need for a radiologist who specialize in reading prostate MRIs, which can be difficult to do, as well as establishing specific rules and guidelines to make prostate cancer diagnoses through multiparametric MRI more consistent globally.
Biography:
Jelle Barentsz, MD, Phd is a Professor of Radiology and Chair Prostate MR - Reference Center, Radboud University Medical Center, Nijmegan, Netherlands. Dr. Barentsz is one of the world’s leading authorities on prostate mp MRI imaging.
Co-interviewers:
John Fortin is a retired Fellow in the Society of Actuaries and a patient advocate
Henry Oat is a Patient Coordinator at Desert Medical Imaging and a patient advocate
Dr. Jelle Barentsz provides his perspective on treating a patient with a rising PSA and is seeking diagnosis options. During this discussion held at the Radiological Society of North America (RSNA) 2017 conference, he shares that he would not recommend a 12-core systematic biopsy because it is not targeted. 40% of patients with a trans-rectal ultrasound guided (TRUS) biopsies will reveal insignificant cancer, which will result in over-diagnosis. Dr. Barentsz recommends multiparametric MRI, which is quick, easy, and can significantly reduce over-diagnoses from 40% to 80%. He also discusses the need for a radiologist who specialize in reading prostate MRIs, which can be difficult to do, as well as establishing specific rules and guidelines to make prostate cancer diagnoses through multiparametric MRI more consistent globally.
Biography:
Jelle Barentsz, MD, Phd is a Professor of Radiology and Chair Prostate MR - Reference Center, Radboud University Medical Center, Nijmegan, Netherlands. Dr. Barentsz is one of the world’s leading authorities on prostate mp MRI imaging.
Co-interviewers:
John Fortin is a retired Fellow in the Society of Actuaries and a patient advocate
Henry Oat is a Patient Coordinator at Desert Medical Imaging and a patient advocate
Related Content:
AUA 2017: Multiparametric MRI – When, Who, and How to Interpret?
AUA 2017: Absence of learning curve impact may let MRI-TRUS fusion guided biopsy up for early diagnosis of prostate cancer
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.
EAU 2017: Controversies in prostate cancer detection: Multiparametric MRI is a must
SIU 2017: Combined Clinical Parameters and Multiparametric MRI for Advanced Risk Modeling of Prostate Cancer - Patient-Tailored Risk Stratification Can Reduce Unnecessary Biopsies
AUA 2017: Multiparametric MRI – When, Who, and How to Interpret?
AUA 2017: Absence of learning curve impact may let MRI-TRUS fusion guided biopsy up for early diagnosis of prostate cancer
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.
EAU 2017: Controversies in prostate cancer detection: Multiparametric MRI is a must
SIU 2017: Combined Clinical Parameters and Multiparametric MRI for Advanced Risk Modeling of Prostate Cancer - Patient-Tailored Risk Stratification Can Reduce Unnecessary Biopsies
E-Newsletters
Free Daily and Weekly newsletters offered by content of interest
The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.